Table 3. Baseline Characteristics in Propensity Score–Matched Cohorta.
| Characteristic | Antidepressant group (n = 166) | No antidepressant group (n = 166) | Standardized difference |
|---|---|---|---|
| Age group, y | |||
| 66-69 | 39 (23.5) | 37 (22.3) | 0.0287 |
| 70-79 | 68 (41.0) | 65 (39.2) | 0.0369 |
| ≥80 | 59 (35.5) | 64 (38.6) | 0.0624 |
| Sex | |||
| Female | 84 (50.6) | 91 (54.8) | 0.0845 |
| Male | 82 (49.4) | 75 (45.2) | 0.0845 |
| Rural home address | 21 (12.7) | 18 (10.8) | 0.0562 |
| Charlson Comorbidity Index, mean (SD) | 2.2 (1.9) | 2.1 (2.1) | 0.0358 |
| eGFR, mean (SD), mL/min/1.73 m2 | 70.4 (29.0) | 70.4 (27.1) | 0.0003 |
| History of substance use disorder | 0 | 0 | 0 |
| Days of linezolid treatment, mean (SD) | 10.6 (6.4) | 10.7 (6.3) | 0.0161 |
| Taking other serotonergic medication(s) | 11 (6.6) | 8 (4.8) | 0.0779 |
Abbreviation: eGFR, estimated glomerular filtration rate.
a
Data are presented as number (percentage) of patients unless otherwise indicated. Listwise deletion was used, so no data were missing in the propensity score–matched cohort.